New stem cell therapy aims to free patients from lifelong blood transfusions

NCT ID NCT04390971

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study tested a new treatment called ET-01 in 3 people with transfusion-dependent beta-thalassemia, a blood disorder that requires regular blood transfusions. The treatment uses the patient's own stem cells, which are modified and then transplanted back. The goal was to see if it is safe and can reduce or eliminate the need for transfusions by helping the body produce healthy red blood cells.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRANSFUSION DEPENDENT BETA-THALASSAEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

beta thalassemia beta-thalassemia major

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Affiliated Hospital of Zunyi Medical University

    Zunyi, Guizhou, 563000, China

  • Institute of Hematology & Blood Diseases Hospital

    Tianjin, Tianjin Municipality, 300020, China

  • The Affiliated Hospital of Guizhou Medical University

    Guiyang, Guizhou, 550004, China